Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety Study for the Treatment of Dysfunctional Uterine Bleeding

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Women 18 years or older~* And with a diagnosis of dysfunctional uterine bleeding without organic pathology~* And with at least one of the following symptoms: prolonged, frequent or excessive bleeding.~Exclusion Criteria:~* The use of steroidal oral contraceptives, or any drug that could alter oral contraception metabolism will be prohibited during the study.~* Women with a history of endometrial ablation or dilatation and curettage within 2 months prior to study start will be excluded.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Estradiol valerate/Dienogest (Natazia, Qlaira, BAY86-5027) (Type: EXPERIMENTAL): A blister consists of 28 tablets taken orally once a day for 28 days (one cycle): 2 days of 3 mg estradiol valerate (EV); 5 days of 2 mg EV + 2 mg dienogest (DNG); 17 days of 2 mg EV + 3 mg DNG; 2 days of 1 mg EV; 2 days of placebo.
- Placebo (Type: PLACEBO_COMPARATOR): Matching placebo to be taken orally daily.

Based on this trial design, predict the completion outcome and termination type (if applicable).